The industry needs to embrace innovation with technology towards novel drug development to remain relevant in the marketplace.

Spooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, ...

Hetero Group founder, B Parthasaradhi Reddy, warns of potential US reciprocal tariffs on Indian pharmaceuticals, which could ...

Warns that Indian pharmaceutical products could become more expensive in the US, reducing their competitiveness in one of the ...

India has emerged as an increasingly significant player in the illicit fentanyl trade, according to a new intelligence report ...

India has emerged as a growing player in the illicit fentanyl trade, a new US intelligence report says, a designation likely ...

The session highlighted existing policy support mechanisms and upcoming opportunities under the PRIP scheme aimed at ...

Indian equity benchmarks advanced on Thursday, driven by gains in heavyweight financials, although a decline in Tata Motors ...

U.S. President Trump imposes 25% tariff on auto imports, spotlight on pharma imports, Indian industry at risk.

India’s specialty chemicals sector is showing early signs of recovery in Q4 FY25, while pharmaceutical exports continue to grow at 8-9%, driven by strong demand for drugs like gRevlimid (blood ...

Starting at Rs 3,500 per injection, with a monthly cost of up to Rs 14,000, Mounjaro enters India’s growing diabetes and ...